Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With WM
Treon SP, et al.
J Clin Oncol · 2018
Key Findings
- ●Ibrutinib highly active as primary therapy in treatment-naive WM
- ●CXCR4 mutation status impacts response to ibrutinib
- ●Durable responses with acceptable safety profile
Referenced in (1 disease)
Validation history
Full log →No validation events recorded yet. Source will be checked on the next kipine-source-validator run.
ID: pmid-30044692DOI: 10.1200/JCO.2018.78.6426PMID: 30044692